Comparing the current results to its competitors, Recursion Pharmaceuticals Inc reported Revenue decrease in the 2 quarter 2026 year on year by -60.1 %, despite the revenue increase by the most of its competitors of 11.25 %, recorded in the same quarter.
December 20, 2024
Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX), a pioneering TechBio company known for its innovative approaches to drug discovery, has recently announced the approval of a substantial grant of inducement restricted stock unit (RSU) awards. On December 19, 2024, the Compensation Committee of Recursion s Board of Directors sanctioned the allocation of 7,952,836 shares of Class A common stock as part of the company s 2024 Inducement Equity Incentive Plan. This award, which covers 230 new employees, was designed as an enticement for their commencement of employment following Recursion s acquisition of Exscientia plc, in accordance with Nasdaq Listing Rule 5635(c)(4).This strategic move aims to attract top talen...
December 20, 2023
Recursion and Enamine Collaborate to Drive Drug Discovery with Enriched Compound Libraries In a significant development for the global drug discovery industry, Recursion Pharmaceuticals Inc has joined forces with Enamine, a leading chemistry-driven drug discovery and preclinical development company. This collaboration aims to leverage Recursion s innovative MatchMaker tool to identify compounds across Enamine s REAL Space that have the potential to bind to high-value targets. This partnership between two industry leaders has the potential to revolutionize the process of compound library screening and facilitate the discovery of novel drug candidates. Recursion Pharmaceuticals Inc has made remarkable ...
Moderna Inc's business model revolves around the development and commercialization of mRNA-based therapeutics and vaccines. They focus on using messenger RNA (mRNA) technology to create drugs that can help prevent and treat various diseases.
Molecular Partners Ag is a biotechnology company that operates on an innovative business model focused on the development of therapeutic drugs. The company utilizes its proprietary DARPin technology platform to create a pipeline of potential treatments for various diseases. Molecular Partners Ag primarily collaborates with strategic partners, including pharmaceutical companies, to advance its drug candidates through preclinical and clinical development stages.
Mesoblast Ltd is a biotechnology company that operates on a business model focused on the development and commercialization of proprietary cell-based regenerative medicines. They aim to transform the treatment of various degenerative diseases by utilizing their patented technology and strategic partnerships with pharmaceutical companies.
Ladrx Corporation operates as a global technology solutions provider, offering a range of products and services in various industries. Their business model revolves around leveraging innovative technologies to develop tailored solutions for their clients, with a focus on enhancing operational efficiency and driving digital transformation. By combining their expertise in multiple domains and maintaining strong partnerships, Ladrx aims to deliver value-driven solutions to meet the evolving needs of businesses worldwide.
Sources:
Recursion Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Recursion Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
